🇺🇸 FDA
Pipeline program

CM336 Plus Isatuximab

IIT2026037

Phase 2 small_molecule active

Quick answer

CM336 Plus Isatuximab for Multiple Myeloma (MM) is a Phase 2 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Multiple Myeloma (MM)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials